BGF MDI HFO 320/14.4/9.6μg

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

COPD (Chronic Obstructive Pulmonary Disease)

Clinical Trial

Last updated: 2/9/2026

Developer

AZN

AstraZeneca PLC

Related Pipeline

Irritable Bowel Syndrome With Constipation (IBS-C)

Muscle Invasive Bladder Cancer

Asthma, Exercise-Induced

Affective Psychosis, Bipolar

Carcinoma, Non-Small-Cell Lung